PCOS Is Now PMOS: What the Rename Means for Your Diagnosis, Care, and Why Peptides Are Reshaping Treatment

Clinical Summary

For decades, a name got in the way of your care. As of May 2026, that name has officially changed. Here is what the rename from PCOS to PMOS means, why it matters more than a single letter, and how peptide-based therapies — particularly GLP-1 receptor agonists and kisspeptin — are now supported by growing clinical evidence for the underlying biology of this condition.

What Just Changed — And Why It Matters More Than a Single Letter

On May 13, 2026, a landmark paper published in The Lancet formally announced what years of patient advocacy and clinical research had been building toward: polycystic ovary syndrome (PCOS) is now officially called polyendocrine metabolic ovarian syndrome (PMOS). [1]

The announcement was made simultaneously at the European Congress of Endocrinology in Prague and represents the conclusion of what researchers are describing as the most rigorous disease-renaming process in medical history — more than a decade of work, 56 leading academic, clinical, and patient organizations, and over 22,000 survey responses from patients, doctors, researchers, and patient charities across every region of the world.[1]

For the 170 million women worldwide living with this condition — roughly 1 in 8 of reproductive age — this is not a semantic update.[2] It is a long-overdue correction that has direct consequences for how you are diagnosed, how doctors understand your symptoms, and what treatments get considered.

If you have spent years being told your condition is about cysts, or been dismissed because you didn't have visible ovarian changes on an ultrasound, the new name starts to explain why.

The Old Name Was Failing Patients — Here Is the Evidence

The term "polycystic ovary syndrome" was coined in 1935 based on the observation that some women with irregular cycles had enlarged ovaries with multiple small follicles visible on the surface. For a long time, those visible follicles were treated as the defining feature of the condition — and the name stuck.

The problem is that this framing was always incomplete, and decades of subsequent research have demonstrated how actively harmful it became.

Most people with PMOS do not have ovarian cysts. A companion paper published alongside the Lancet renaming paper confirmed that there is no increase in abnormal ovarian cysts in this condition. [1] The "polycystic" follicles seen on ultrasound are, more accurately, arrested follicles — the consequence of dysfunctional ovulation, not the cause. Calling the condition polycystic implied a gynecological origin and directed clinical attention toward the ovaries when the underlying dysfunction was happening upstream: in the hypothalamus, in insulin signaling pathways, in androgen metabolism.

The name contributed directly to underdiagnosis. An estimated 70% of people with PMOS remain undiagnosed globally. [2] That number is not just a function of limited healthcare access — it reflects a diagnostic framework that required specific ovarian findings that many women with the condition do not have. Women who presented with insulin resistance, elevated androgens, cycle irregularity, or metabolic risk without visible ovarian changes were frequently missed or told their symptoms were unrelated.

It generated stigma that delayed treatment-seeking. In survey after survey conducted over the 11-year renaming process, patients reported that the name made them feel their condition was primarily about reproductive failure or fertility. [1] Many women did not seek care until fertility became a concern, missing the window for early metabolic intervention that could have reduced their cardiovascular and diabetes risk by midlife.

It fragmented care. Because the name pointed to the ovaries, women with PMOS were routed to gynecologists — often when endocrinologists, metabolic specialists, and cardiologists were equally or more relevant to their care. The result was a condition managed in silos, with reproductive symptoms addressed separately from metabolic ones, and the psychological burden of the syndrome rarely addressed at all. [8]

Professor Helena Teede, endocrinologist at Monash University in Australia and lead author of the Lancet paper, has spent more than 25 years studying this condition. Her assessment is direct: "By calling this condition polycystic ovary, we're missing the big picture."

Breaking Down the New Name: What PMOS Actually Tells You

Polyendocrine — The condition involves multiple endocrine systems simultaneously. Insulin, androgens (testosterone, DHEA-S), LH, FSH, and cortisol are all dysregulated and interact with one another. No single hormonal axis is the cause; the dysfunction is distributed across the endocrine system. [5]

Metabolic — Insulin resistance is the central pathophysiological feature of PMOS, present in an estimated 65–80% of cases regardless of body weight. [5] Metabolic complications — elevated cardiovascular risk, progression toward type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease — are not secondary features. They are core to the biology and were obscured by a name that suggested the problem was structural and ovarian.

Ovarian — The ovaries are a target organ of PMOS, not its origin. They experience the downstream consequences of hormonal and metabolic dysregulation: follicular arrest, androgen overproduction, disrupted ovulation. Keeping "ovarian" in the name maintains recognition for the existing patient community and acknowledges the reproductive dimension — while correctly repositioning the ovaries as affected organ rather than primary driver.

Syndrome — This remains accurate. PMOS is a clinical syndrome defined by a constellation of findings, not a single disease with a single cause. Different women present with different combinations of its features, which is why no single treatment protocol works for everyone.

A three-year transition period has been built into the rename, during which PCOS and PMOS will be treated as interchangeable in clinical practice. [8] The changes will cascade into clinical guidelines, medical education curricula, and international disease classification systems — including the ICD — over that period.

The Biology of PMOS: What Is Actually Happening in Your Body

Understanding PMOS requires understanding four overlapping dysfunctions that amplify each other in a self-sustaining feedback loop. Peptide therapy becomes clinically relevant specifically because several peptides target discrete points in this loop.

1. Insulin Resistance and Hyperinsulinemia

The majority of women with PMOS have measurable insulin resistance — the state in which cells throughout the body respond poorly to insulin's signaling. The pancreas compensates by producing more insulin, creating chronically elevated insulin levels (hyperinsulinemia) even when blood glucose appears normal. [5]

This matters for PMOS specifically because the ovaries do not become insulin-resistant at the same rate as peripheral tissues. Ovarian cells retain insulin sensitivity, which means that high circulating insulin continues to stimulate them — specifically, to stimulate the theca cells that produce androgens. The result is excess testosterone and DHEA-S production driven directly by insulin levels, not by any inherent ovarian dysfunction.

This is why addressing insulin resistance is the highest-leverage intervention in PMOS management. It interrupts the cascade at its origin. For a deeper look at what labs to track — including fasting insulin, HOMA-IR, and androgen panels — see Meto's PCOS Blood Test Results Guide.

2. Androgen Excess (Hyperandrogenism)

Elevated androgens — detectable on labs as elevated total or free testosterone, elevated DHEA-S, or elevated androstenedione — drive the most visible symptoms of PMOS: hirsutism (excess facial and body hair), acne, androgenic alopecia (scalp hair thinning at the crown), and cycle disruption. They also directly interfere with follicle development in the ovary, preventing the normal maturation process that leads to ovulation. [5]

Androgen excess in PMOS is almost always secondary — driven by hyperinsulinemia, LH dysregulation, or both. Sex hormone-binding globulin (SHBG), a protein that binds testosterone and renders it inactive, is suppressed by high insulin, which means more free (biologically active) testosterone circulates even when total testosterone levels appear borderline.

3. LH/FSH Dysregulation

In healthy reproductive cycling, the hypothalamus releases gonadotropin-releasing hormone (GnRH) in a pulsatile rhythm that drives balanced secretion of both LH (luteinizing hormone) and FSH (follicle-stimulating hormone) from the pituitary. The ratio of these hormones is carefully calibrated to support the two phases of the ovarian cycle.

In PMOS, GnRH pulse frequency is abnormally accelerated. This shifts pituitary output toward LH dominance — the elevated LH:FSH ratio seen on labs in many PMOS patients. LH hyperstimulation drives thecal androgen production while FSH suppression prevents granulosa cells from converting those androgens to estrogen and maturing follicles through to ovulation. [5]

The result is follicular arrest: multiple small, undeveloped follicles that accumulate in the ovary — the "polycystic" appearance on ultrasound — not because cysts are forming, but because normal follicle maturation is blocked.

The key upstream regulator of GnRH pulse frequency is kisspeptin — which is precisely why kisspeptin-targeting peptides are a legitimate area of clinical investigation for PMOS. [3]

4. Chronic Low-Grade Inflammation

Elevated markers of inflammation — C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) — are consistently found in women with PMOS. Critically, this inflammatory profile is present in lean women with PMOS and in the absence of obesity, which establishes inflammation as a core feature of the syndrome rather than a consequence of excess adiposity. [5]

Chronic inflammation worsens insulin signaling at the cellular level and contributes independently to cardiovascular risk. [6] It also appears to amplify androgen sensitivity in target tissues, worsening hirsutism and acne beyond what androgen levels alone predict.

Why Peptides Are Particularly Relevant to PMOS Biology

The reason peptide therapy has moved to the center of the PMOS treatment conversation is structural. The four dysfunctions described above all involve disruptions to molecular signaling pathways — the kind of targeted, receptor-level problem that peptides are specifically designed to address.

Standard PMOS treatments work at a blunt, systemic level. Oral contraceptives suppress androgen production globally by shutting down the HPG axis — they do not address insulin resistance, and their protective effects end when the medication stops. Metformin modestly improves insulin sensitivity but does not address LH dysregulation or the hypothalamic-pituitary signaling defects upstream. Neither directly addresses inflammation.

Peptides, by contrast, can engage specific receptors within specific signaling cascades. A GLP-1 receptor agonist improves insulin sensitivity with high specificity. Kisspeptin-targeting therapies work directly at the GnRH pulse generator. The precision is clinically relevant because PMOS is a precision problem — a dysregulation of specific molecular signals that requires targeted correction, not broad suppression. For a foundational understanding of how peptides work in the body and a breakdown of the 7 types of therapeutic peptides, Meto's clinical library covers both in accessible terms.

Important clinical note: What follows is a breakdown of the clinical evidence landscape as it currently stands. The evidence is not uniform across peptides. GLP-1 receptor agonists have the strongest and most mature clinical data in PMOS populations. Other peptides — kisspeptin, sermorelin, follistatin — are in earlier phases of clinical research. BPC-157, despite widespread online discussion, has no completed human randomized controlled trials in any indication. Understanding where each peptide sits on that evidence spectrum is essential to informed clinical decision-making.

GLP-1 Receptor Agonists: The Strongest Peptide Evidence in PMOS

How They Work

Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone secreted by the gut in response to food. It stimulates insulin release in a glucose-dependent manner, slows gastric emptying, reduces appetite through hypothalamic signaling, and has direct anti-inflammatory effects on multiple tissue types. GLP-1 receptors are expressed not just in the pancreas but also in the liver, adipose tissue, the hypothalamus, and the ovary itself. [4]

GLP-1 receptor agonists — pharmaceutical-grade peptides that mimic and extend the action of endogenous GLP-1 — reduce hyperinsulinemia, the primary driver of ovarian androgen overproduction in PMOS. For a broader clinical overview of how this drug class has entered mainstream medicine, see Meto's article on peptide therapy and mainstream medicine in 2026.

Semaglutide (Ozempic / Wegovy)

Semaglutide is currently the most studied GLP-1 receptor agonist in PMOS populations. Randomized controlled trial data from 2023 demonstrated that semaglutide significantly reduced testosterone levels and improved menstrual regularity in women with PMOS — with hormonal improvements that extended beyond what weight loss alone could explain, indicating a direct, weight-independent effect on the ovarian androgen pathway. [4]

Analyses from the broader STEP trial program showed reductions in free androgen index and improvements in cycle frequency in reproductive-age women. The mechanism is relatively well-mapped: semaglutide reduces fasting insulin → lowers LH-mediated ovarian androgen secretion → increases SHBG → reduces free testosterone → reduces hirsutism, improves ovulation, and, in many cases, restores cycle regularity.

Ozempic (semaglutide 0.5–2mg, weekly injection) is approved for type 2 diabetes. Wegovy (semaglutide 2.4mg, weekly injection) is approved for chronic weight management. Both are used off-label for PMOS, supported by a growing body of PMOS-specific clinical data. In women with PMOS where metabolic features predominate — elevated fasting insulin, dyslipidemia, elevated BMI, or a family history of type 2 diabetes — semaglutide sits at the top of the clinical consideration hierarchy.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide is a dual agonist targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual mechanism produces greater reductions in insulin resistance and visceral adiposity compared to GLP-1 agonism alone, which is clinically significant in PMOS because visceral fat is both an androgen-producing and inflammation-amplifying tissue.[4]

For women with PMOS who have a strong metabolic phenotype — particularly those with insulin resistance accompanied by significant central adiposity — tirzepatide's greater metabolic potency may offer advantages over semaglutide. Early data from the SURMOUNT trial program showed hormonal improvements consistent with semaglutide findings.

Liraglutide

Liraglutide has the longest track record in PMOS research and was the first GLP-1 agonist to show cycle restoration in clinical trials. [4] While semaglutide has largely superseded it on efficacy and convenience (weekly vs. daily dosing), liraglutide data provides the foundational mechanistic evidence underpinning GLP-1 use in PMOS and remains relevant in clinical discussions.

What GLP-1 Agonists Do Not Do

They do not directly address LH/FSH dysregulation at the hypothalamic level. In women whose primary PMOS feature is disrupted GnRH pulse frequency rather than insulin resistance — the lean PMOS phenotype, without significant metabolic markers — GLP-1 receptor agonists may produce less benefit. This is where other peptides become relevant.

Kisspeptin: The HPG Axis Peptide with the Most Clinical Promise

The Biology

Kisspeptin is a neuropeptide produced in the hypothalamus that serves as the master regulator of GnRH pulse secretion. By binding to its receptor (Kiss1R), kisspeptin triggers GnRH release from the hypothalamus, which in turn drives LH and FSH secretion from the pituitary. [7]

In PMOS, the kisspeptin signaling system appears to be dysregulated in a way that drives the abnormally rapid GnRH pulse frequency responsible for LH hypersecretion. Research published in PLOS ONE in February 2026 demonstrated that kisspeptin improves local ovarian insulin resistance in PCOS by modulating the PI3K/AKT/GLUT4 signaling pathway — a finding that suggests kisspeptin's role in PMOS extends beyond its GnRH regulatory function to include direct ovarian effects on insulin signaling. [3]

What the Clinical Research Shows

Kisspeptin-54 has been studied in human trials for ovulation induction in women with PCOS, with results demonstrating that kisspeptin can successfully trigger the LH surge required for ovulation when administered at specific points in the cycle. [7] King's College London has been a leading center for this research, with Dr. Waljit Dhillo's group publishing multiple studies showing kisspeptin's ability to induce ovulation in anovulatory women with PCOS without the hyperstimulation risk associated with conventional gonadotropin protocols.

The therapeutic logic is precise: rather than globally suppressing the HPG axis (as oral contraceptives do) or stimulating it indiscriminately (as gonadotropin injections do), kisspeptin may offer cycle-specific, receptor-targeted restoration of normal ovulatory patterning.

For lean women with PMOS whose primary presentation is anovulation and elevated LH:FSH ratio without significant metabolic markers, kisspeptin-directed therapy addresses the problem at its neuroendocrine origin.

Current Availability

This distinction matters clinically: kisspeptin therapy is currently available only within trial settings and is not yet a prescribable clinical option outside of research institutions. It is not available as a commercial peptide product. Any product marketed as "kisspeptin therapy" outside of a regulated clinical trial should be approached with significant caution regarding purity, dosing accuracy, and legal status in your jurisdiction. Meto's guide on pharmaceutical-grade versus research peptides explains this distinction in full.

Sermorelin and the Growth Hormone Axis: An Indirect but Relevant Pathway

Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) and holds an FDA-approved track record for assessing and addressing growth hormone deficiency. It stimulates the pituitary to produce growth hormone (GH) in a pulsatile, physiologically regulated manner, which is important because GH itself intersects with both insulin signaling and androgen metabolism in women with PMOS.

In the PMOS context, growth hormone influences IGF-1 production, which modulates insulin sensitivity and interacts with androgen production pathways in the ovary. Some women with PMOS show relative GH deficiency or blunted GH pulsatility — a pattern that may be amenable to sermorelin-supported intervention.

The evidence here is less direct than for GLP-1 agonists. Sermorelin is not being studied in PMOS-specific clinical trials at the same scale. However, for women with PMOS who also show signs of impaired GH axis function — fatigue, impaired body composition, blunted recovery — sermorelin is worth discussing with a metabolic clinician as part of a comprehensive hormonal evaluation.

Follistatin: Androgen and AMH Regulation

Follistatin is an endogenous protein-peptide that binds and neutralizes activin, a signaling molecule that suppresses FSH production and is implicated in the hormonal environment that drives androgen excess in PMOS. Elevated AMH (anti-Müllerian hormone) — consistently found in PMOS — is partly regulated by activin-follistatin balance. [5]

Exogenous follistatin is under investigation for its potential to normalize FSH:LH ratio, improve granulosa cell function, and reduce androgen overproduction by restoring the activin-follistatin axis. Early animal model data shows meaningful ovarian effects, and there is active clinical research interest.

Like kisspeptin, follistatin is not yet a clinically available therapeutic option. It is being studied — and the biology is legitimate — but it is not a treatment you should expect to access outside of a trial setting, and it should not be confused with unregulated research compounds sold under the same name.

BPC-157: Honest Evaluation of a Widely Discussed Compound

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a stomach protein. It circulates heavily in online PMOS and hormonal health communities, often described as beneficial for gut health, inflammation, and hormonal regulation.

The honest clinical assessment: BPC-157 has no completed randomized controlled trials in humans, in any indication. The mechanistic rationale for its use is largely extrapolated from animal studies, and it has no regulatory approval in any country. While the anti-inflammatory pathways implicated in animal research are theoretically relevant to PMOS biology, there is no published human trial data demonstrating efficacy or establishing safe dosing parameters in PMOS populations.

If you are considering BPC-157 based on online recommendation, the appropriate guidance is to bring that conversation to a qualified metabolic clinician who can contextualize the evidence honestly — and to understand that you would be taking an unregulated research compound with no established safety data in humans. Meto's breakdown of pharmaceutical-grade versus research peptides covers exactly what that distinction means for safety and sourcing.

Matching the Right Peptide to Your PMOS Phenotype

PMOS presents differently in different women. The reason no single treatment works for everyone is that the relative contribution of each of the four core dysfunctions varies by individual. A clinically informed peptide strategy should be phenotype-matched.

Metabolic-dominant PMOS (elevated fasting insulin, insulin resistance confirmed on labs, central adiposity, dyslipidemia, elevated cardiovascular risk markers): GLP-1 receptor agonists — semaglutide or tirzepatide — provide the most direct mechanistic benefit. This phenotype responds well to insulin pathway intervention because hyperinsulinemia is the proximal driver of androgen excess. [4]

Lean PMOS with HPG axis predominance (elevated LH:FSH ratio, primary anovulation, limited metabolic markers, lower BMI): The upstream neuroendocrine dysfunction is the primary target. Kisspeptin-based approaches address this most directly, though they remain in trial settings. GnRH analogue protocols and clomiphene remain current clinical options for ovulation induction while HPG-targeting peptide therapies mature. [7]

Mixed phenotype (insulin resistance combined with elevated LH and significant androgen excess): A combination approach — insulin sensitization through GLP-1 agonists alongside strategies addressing GnRH pulse frequency — is most appropriate. This patient population benefits from multidisciplinary care that brings endocrinology and reproductive medicine together. [1]

PMOS with significant inflammation markers (elevated hs-CRP, IL-6 in the absence of active infection, persistent symptoms disproportionate to hormone levels): Anti-inflammatory approaches are part of the clinical picture here. GLP-1 agonists have documented anti-inflammatory effects beyond their insulin-sensitizing function.[4] Lifestyle-based interventions — specific dietary patterns with established anti-inflammatory evidence — are integral rather than optional for this phenotype.

Key Lab Markers to Track in PMOS — Before and During Peptide Therapy

A peptide protocol for PMOS should be guided by objective biomarker tracking, not symptom response alone. For a comprehensive guide on interpreting these results in the PMOS context, Meto's PCOS Blood Test Results Guide covers each marker in clinical detail. The following are the core panels your clinician should assess at baseline and monitor during treatment:

Metabolic panel: Fasting insulin, fasting glucose, HbA1c (or HOMA-IR calculated from glucose and insulin). These establish insulin resistance severity and track the primary target of GLP-1 agonist therapy.

Androgen panel: Total testosterone, free testosterone, SHBG, DHEA-S, androstenedione. Tracking free testosterone and SHBG together gives a clearer picture of androgenic activity than total testosterone alone.

HPG axis: LH, FSH, LH:FSH ratio (timing matters — ideally early follicular phase if cycling). AMH gives a measure of ovarian reserve and follicle pool, which is characteristically elevated in PMOS.

Metabolic health markers: Fasting lipid panel (LDL, HDL, triglycerides), hs-CRP for inflammatory status, liver function tests (NAFLD is a PMOS comorbidity that is underscreened). [6]

Prolactin and thyroid: To exclude secondary causes of cycle disruption that can overlap symptomatically with PMOS.

What the Rename Means for Your Clinical Interactions Going Forward

The three-year transition period means that PCOS and PMOS will be used interchangeably in clinical settings while guidelines, education, and classification systems are updated.[8] In practical terms:

Your diagnosis and medical records may still reference PCOS for the near future — this is expected and does not mean your provider is uninformed about the rename. What you can reasonably expect to change over the transition period is the framing of your care: increased attention to metabolic markers alongside reproductive ones, earlier cardiovascular risk screening, and greater willingness to engage with insulin-sensitizing approaches even when fertility is not your immediate concern.

The rename also strengthens the patient case for comprehensive metabolic workup at diagnosis. If PMOS is formally a metabolic-endocrine syndrome, the standard of care should include metabolic assessment — fasting insulin, fasting glucose, lipid panel, and cardiovascular risk profiling — not just cycle history and ultrasound.

The Endocrine Society, which was among the 56 organizations involved in the renaming process, has committed to updating clinical guidelines to reflect the new framing. [8] This will take time to propagate through clinical practice, but the direction is clear.

Finding Specialized Care for PMOS

The multisystem nature of PMOS means the most effective care is not siloed. You ideally want a clinician or clinical team that treats PMOS as a metabolic-endocrine-reproductive condition simultaneously, not sequentially across different specialty appointments.

Metabolic medicine physicians with experience in PMOS — or reproductive endocrinologists with metabolic training — are best positioned to integrate all four dimensions of the syndrome into a coherent treatment plan. When evaluating a provider, the questions worth asking are: Do they order a metabolic panel (including fasting insulin) as part of standard PMOS workup? Do they consider GLP-1 receptor agonists in the conversation for women with insulin resistance, even without a diabetes diagnosis? Do they engage with the psychological burden of the condition as a clinical matter, not an afterthought?

Clinical Takeaways

• PCOS is now PMOS — polyendocrine metabolic ovarian syndrome. The rename, published in The Lancet on May 13, 2026, reflects 14 years of global clinical consensus work involving 22,000 voices across 56 organizations. [1]
• The old name was actively harmful. It pointed to the wrong organ, generated stigma, drove underdiagnosis, and fragmented care. An estimated 70% of the 170 million women with PMOS remain undiagnosed globally. [2]
• PMOS is a metabolic-endocrine disorder first. Insulin resistance, androgen excess, LH/FSH dysregulation, and chronic inflammation are the four core, causally linked dysfunctions. The ovaries are a target, not the origin. [5]
• GLP-1 receptor agonists have the strongest peptide evidence for PMOS. Semaglutide and tirzepatide address the insulin resistance that drives androgen overproduction, with trial data showing improvements in testosterone levels, SHBG, and cycle regularity beyond weight loss alone. [4]
• Kisspeptin is the most mechanistically targeted HPG-axis peptide in clinical investigation, with human trial data supporting its use for ovulation induction in PMOS — though it remains in trial settings and is not yet a prescribable option. [3],[7]
• Phenotype matching matters. Metabolic-dominant PMOS responds best to insulin pathway interventions. Lean PMOS with primary HPG dysregulation is the target phenotype for kisspeptin and GnRH-axis strategies.
• BPC-157 has no human trial data in PMOS. Online enthusiasm does not constitute clinical evidence.

This article is written for informational purposes by the Meto physician team and does not constitute medical advice or establish a physician-patient relationship. GLP-1 receptor agonists require a prescription and clinical evaluation. Discuss any treatment considerations with a qualified metabolic clinician.